MAPT and Alzheimer disease: Recent profiling of phosphorylated tau peptides in cerebrospinal fluid (CSF) by mass spectrometry has revealed 11 sites that are increased by at least 40% in the CSF of patients with AD compared to controls (Russell et al., 2017).